{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:24:35Z","timestamp":1789424675698,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T00:00:00Z","timestamp":1501200000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T00:00:00Z","timestamp":1501200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK063158"],"award-info":[{"award-number":["R01 DK063158"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s10620-017-4687-7","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T01:20:54Z","timestamp":1501204854000},"page":"2428-2432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Latiglutenase Improves Symptoms in Seropositive Celiac Disease Patients While on a Gluten-Free Diet"],"prefix":"10.1007","volume":"62","author":[{"given":"Jack A.","family":"Syage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H. R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitan","family":"Khosla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"key":"4687_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/MOG.0b013e3283365263","volume":"26","author":"A Rubio-Tapia","year":"2010","unstructured":"Rubio-Tapia A, Murray JA. Celiac disease. Curr Opin Gastroenterol. 2010;26:116\u2013122.","journal-title":"Curr Opin Gastroenterol"},{"key":"4687_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/1756283X13492580","volume":"6","author":"CA Tennyson","year":"2013","unstructured":"Tennyson CA, Simpson S, Lebwohl B, Lewis S, Green PH. Interest in medical therapy for celiac disease. Ther Adv Gastroenterol. 2013;6:358\u2013364.","journal-title":"Ther Adv Gastroenterol"},{"key":"4687_CR3","first-page":"27","volume":"20","author":"I Aziz","year":"2011","unstructured":"Aziz I, Evans KE, Papageorgiou V, Sanders DS. Are patients with coeliac disease seeking alternative therapies to a gluten-free diet? J Gastrointestin Liver Dis. 2011;20:27\u201331.","journal-title":"J Gastrointestin Liver Dis"},{"key":"4687_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/gastro\/gov006","volume":"3","author":"K Gottlieb","year":"2015","unstructured":"Gottlieb K, Dawson J, Hussain F, Murray JA. Development of drugs for celiac disease: review of endpoints for phase 2 and 3 trials. Gastroenterol Rep (Oxf). 2015;3:91\u2013102.","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"4687_CR5","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1053\/j.gastro.2014.02.031","volume":"146","author":"ML Lahdeaho","year":"2014","unstructured":"Lahdeaho ML, Kaukinen K, Laurila K, et al. Glutenase alv003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology. 2014;146:1649\u20131658.","journal-title":"Gastroenterology"},{"key":"4687_CR6","doi-asserted-by":"publisher","first-page":"13106","DOI":"10.1021\/jacs.5b08325","volume":"137","author":"C Wolf","year":"2015","unstructured":"Wolf C, Siegel JB, Tinberg C, et al. Engineering of kuma030: a gliadin peptidase that rapidly degrades immunogenic gliadin peptides in gastric conditions. J Am Chem Soc. 2015;137:13106\u201313113.","journal-title":"J Am Chem Soc"},{"key":"4687_CR7","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1053\/j.gastro.2015.02.008","volume":"148","author":"DA Leffler","year":"2015","unstructured":"Leffler DA, Kelly CP, Green PH, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148:1311\u20131319.","journal-title":"Gastroenterology"},{"key":"4687_CR8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1053\/j.gastro.2007.05.028","volume":"133","author":"J Gass","year":"2007","unstructured":"Gass J, Bethune MT, Siegel M, Spencer A, Khosla C. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology. 2007;133:472\u2013480.","journal-title":"Gastroenterology"},{"key":"4687_CR9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ajcn\/85.1.160","volume":"85","author":"C Catassi","year":"2007","unstructured":"Catassi C, Fabiani E, Iacono G, et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr. 2007;85:160\u2013166.","journal-title":"Am J Clin Nutr"},{"key":"4687_CR10","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1053\/j.gastro.2016.11.004","volume":"152","author":"JA Murray","year":"2017","unstructured":"Murray JA, Kelly CP, Green PH, et al. No difference between latiglutenase and placebo in reducing villous atrophy or improving symptoms in patients with symptomatic celiac disease. Gastroenterology. 2017;152:787\u2013798.","journal-title":"Gastroenterology"},{"key":"4687_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1053\/j.gastro.2016.07.025","volume":"151","author":"D Leffler","year":"2016","unstructured":"Leffler D, Kupfer SS, Lebwohl B, Bugin K, Griebel D, et al. Development of celiac disease therapeutics: report of the third gastroenterology regulatory endpoints and advancement of therapeutics workshop. Gastroenterology. 2016;151:407\u2013411.","journal-title":"Gastroenterology"},{"key":"4687_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/jjval201612016","author":"DA Leffler","year":"2017","unstructured":"Leffler DA, Acaster S, Gallop K, et al. A novel patient-derived conceptual model of the impact of celiac disease in adults: implications for patient-reported outcome and hela-related quality-of-life instrument development. Value Health. 2017. doi:\n                    10.1016\/jjval201612016\n                    \n                  .","journal-title":"Value Health"},{"key":"4687_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312762","author":"P Hindryckx","year":"2016","unstructured":"Hindryckx P, Levesque BG, Holvoet T, et al. Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. Gut. 2016. doi:\n                    10.1136\/gutjnl-2016-312762\n                    \n                  .","journal-title":"Gut"},{"key":"4687_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.cgh.2006.12.006","volume":"5","author":"DA Leffler","year":"2007","unstructured":"Leffler DA, Dennis M, Hyett B, Kelly E, Schuppan D, Kelly CP. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol. 2007;5:445\u2013450.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4687_CR15","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/j.1572-0241.2002.05917.x","volume":"97","author":"AS Abdulkarim","year":"2002","unstructured":"Abdulkarim AS, Burgart LJ, See J, Murray JA. Etiology of nonresponsive celiac disease: results of a systematic approach. Am J Gastroenterol. 2002;97:2016\u20132021.","journal-title":"Am J Gastroenterol"},{"key":"4687_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.dld.2006.07.014","volume":"39","author":"P Brar","year":"2007","unstructured":"Brar P, Kwon GY, Egbuna I, et al. Lack of correlation of degree of villous atrophy with severity of clinical presentation of coeliac disease. Dig Liver Dis. 2007;39:26\u201329.","journal-title":"Dig Liver Dis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-017-4687-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4687-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4687-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T10:38:04Z","timestamp":1589711884000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-017-4687-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,28]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["4687"],"URL":"https:\/\/doi.org\/10.1007\/s10620-017-4687-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727849956.793561394","asserted-by":"object"}]},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,28]]},"assertion":[{"value":"7 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JAS is a founder of and owns stock in ImmunogenX. JAM has received grant support from the National Institutes of Health, Alvine Pharmaceuticals, and Alba Therapeutics; receives ongoing support from Oberkotter Foundation and Broad Medical Research Program at CCFA; serves on the advisory board of Celimmune, LLC and ImmunogenX; was a consultant to, BioLineRx, GlaxoSmithKline (GSK), Genentech, and Glenmark Pharmaceuticals Ltd; and is a consultant to ImmunosanT, Institute for Protein Design (PvP Biologics), Takeda Pharmaceutical Company, Ltd., Innovate Biopharmaceuticals, Inc., and Intrexon. PHRG is an advisor to ImmusanT and ImmunogenX. CK is a director of Protagonist Pharmaceuticals and an advisor to Sitari Pharmaceuticals and holds stock in both companies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}